Tokyo University Team Finds Energy Consumption Controlling Protein That Could Lead To Anti-Obesity Drug
This article was originally published in PharmAsia News
A Tokyo University research team discovered a mechanism to control the onset of irregular energy consumption in muscles. The group focused on ruppel-like zinc-finger transcription factor 5, a factor known for causing vascular and heart disease, The team found that KLF5 plays a role coordinating DNAs which promote fatty acid burning and energy consumption. (Click here for more - Japanese language
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.